Online inquiry

IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9914MR)

This product GTTS-WQ9914MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9914MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9142MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ1171MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ7243MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ13046MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ1227MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ2406MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ9928MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ8139MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW